Relatlimab y nivolumab en el tratamiento del melanoma

Video Experimental Relacionado

Updated: Aug 16, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Lewis Au¹, James Larkin², Samra Turajlic³

¹Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC 3010, Australia; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.

|December 23, 2022

Resumen

La inmunoterapia combinada con bloqueadores de LAG-3 y PD-1 es prometedora para el melanoma. Los ensayos clínicos evaluaron el relatlimab y el nivolumab como tratamiento de primera línea para el melanoma avanzado.

Área de la Ciencia:

Inmunología
En el campo de la oncología
Ensayos clínicos

Sus antecedentes:

El bloqueo combinado de LAG-3 y PD-1 es una nueva estrategia terapéutica para el melanoma.
El melanoma metastásico, resecable, de alto riesgo y con nódulos positivos requiere tratamientos efectivos de primera línea.

Objetivo del estudio:

Evaluar la eficacia de la combinación de relatlimab y nivolumab como tratamiento de primera línea para el melanoma metastásico, resecable y de alto riesgo.

Principales métodos:

Se llevaron a cabo dos ensayos clínicos.
Los pacientes recibieron tratamiento de primera línea con relatlimab y nivolumab.

Principales resultados:

La terapia combinada demostró eficacia en el tratamiento del melanoma avanzado.
Resultados específicos de Tawbi y otros. y Amaria y otros. Se publicaron en The New England Journal of Medicine y en Nature, respectivamente.

Conclusiones:

El bloqueo combinado de LAG-3 y PD-1 representa un avance significativo en el tratamiento del melanoma.
Relatlimab y nivolumab ofrecen una nueva opción de primera línea para pacientes con melanoma de alto riesgo.

Más Videos Relacionados

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Videos de Conceptos Relacionados

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...